Alia Therapeutics is an Italian biotech start-up developing innovative treatments for incurable genetic diseases based on gene editing technology.

Alia Therapeutics aims to bring gene editing to the next level of specificity, making it more suitable for applications in the clinical environment. The proprietary synergic core technologies increase the precision of genetic modifications and reduce the risks for patients. The company was founded in October 2018 by a group of researchers from CIBIO, (biotech department – University of Trento). In the last few years Alia Therapeutic closed three rounds of fundraising with commitment from several Institutional Investors.

Alia Therapeutics entered in Atlante Seed’s portfolio in 2021 and in Indaco Bio portfolio in 2023.